Impact of Clinician and Practice Characteristics on Utilization of and Attitudes Toward Long-Acting Injectable Antipsychotics in Schizophrenia: A Survey of US-Practicing Psychiatric Clinicians (DECIDE)

Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases. Methods: In DECIDE, US-based psychiatric clinicians were surveyed regarding their perceptions of and experiences with long-acting injectable antipsychotics (LAIs) for schizophrenia. Results: Of 380 respondents, 169 (44%) practiced in urban areas, 161 (42%) in suburban areas, and 50 (13%) in rural areas. Clinicians in the Western region (n=75) averaged more time with patients during follow-up appointments than those in the Northeast (n=95), Midwest (n=62), and South (n=148; 28.9 vs 25.6/24.2/23.8 minutes; all PShort Description: Psychiatric clinicians were surveyed regarding their perceptions of and experiences with long-acting injectable antipsychotics (LAIs) for schizophrenia. Patient demographics and insurance coverage differed across regions, clinician types, locations (urban, suburban, rural), and settings (community, academic), as well as use of and attitudes toward LAIs. These results suggest that clinicians who treated patients with limited resources (ie, use Medicaid, rural vs urban location) had a more positive attitude toward LAIs.Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D, Inc.